Commercial sponsorship integrates EvE Bio's growing field‑defining "pharmome" map - 385,572 rigorously confirmed drug–target interactions across 159 validated targets - into DrugBank's intelligence ...
Upstream Bio, Inc. presented data at the European Academy of Allergy & Clinical Immunology Congress highlighting the advantages of verekitug, a treatment targeting the TSLP receptor, over tezepelumab, ...
Unprecedented resource, created with Cedars-Sinai, to accelerate ALS research and drive development of targeted therapies globally NEW ORLEANS, [November 14, 2024] — In a landmark continuing ...
Korro Bio, Inc. (KRRO) is a biotech that is working on advancing its RNA editing platform OPERA to treat certain types of disorders. The first RNA edited oligonucleotide drug of its kind from this ...
Passage Bio, Inc. announced interim results from its PBFT02 clinical trial for frontotemporal dementia (FTD) patients with the GRN mutation, revealing significant increases in cerebrospinal fluid (CSF ...
NEW ORLEANS--(BUSINESS WIRE)--In a landmark continuing collaboration, Answer ALS and Cedars-Sinai have announced the completed availability of the largest amyotrophic lateral sclerosis (ALS) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback